XALATAN Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Xalatan, and what generic alternatives are available?

Xalatan is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xalatan

A generic version of XALATAN was approved as latanoprost by AMRING PHARMS on March 22^nd, 2011.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for XALATAN?
What are the global sales for XALATAN?
What is Average Wholesale Price for XALATAN?

Summary for XALATAN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	76
Patent Applications:	6,239
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for XALATAN
What excipients (inactive ingredients) are in XALATAN?	XALATAN excipients list
DailyMed Link:	XALATAN at DailyMed

Drug patent expirations by year for XALATAN

Recent Clinical Trials for XALATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 4
Icahn School of Medicine at Mount Sinai	Phase 4
CHA University	Phase 4

See all XALATAN clinical trials

Pharmacology for XALATAN

Drug Class	Prostaglandin Analog

US Patents and Regulatory Information for XALATAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	AT	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for XALATAN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	⤷ Sign Up	⤷ Sign Up
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	⤷ Sign Up	⤷ Sign Up
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	⤷ Sign Up	⤷ Sign Up
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	⤷ Sign Up	⤷ Sign Up
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for XALATAN

See the table below for patents covering XALATAN around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Spain	2193901		⤷ Sign Up
Germany	68929435		⤷ Sign Up
Denmark	175842		⤷ Sign Up
Hong Kong	159095	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension	⤷ Sign Up
Netherlands	970039		⤷ Sign Up
Japan	H03501025		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for XALATAN

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	C970039	Netherlands	⤷ Sign Up	PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
0364417	97C0128	France	⤷ Sign Up	PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
3461484	132021000000068	Italy	⤷ Sign Up	PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
0364417	9690031-1	Sweden	⤷ Sign Up	PRODUCT NAME: LATANOPROST
1225168	91541	Luxembourg	⤷ Sign Up	91541, EXPIRES: 20110718
3461484	21C1024	France	⤷ Sign Up	PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for XALATAN

Recent Clinical Trials for XALATAN

Pharmacology for XALATAN

Make Better Decisions: Try a trial or see plans & pricing